AstraZeneca makes vaccines purchase

Gibson, Jane
April 2007
ICIS Chemical Business;4/30/2007, Vol. 2 Issue 64, p5
Trade Publication
The article reports on the acquisition of U.S. biotechnology firm MedImmune by Astrazeneca. The move by Astrazeneca is aimed at accelerating its biologics strategy and give it access to the vaccines market for the first time. MedImmune's key products include the FluMist nasal spray flu vaccine and the monoclonal antibody Synagis, used to treat infectious respiratory disease. AstraZeneca's first-quarter 2007 sales rose by 9% to $6.97 billion.


Related Articles

  • AstraZeneca immunizes pipeline. Mirasol, Feliza // ICIS Chemical Business Americas;5/14/2007, Vol. 271 Issue 19, p36 

    The article reports on the planned acquisition of Gaithersburg, Maryland-based biotechnology company MedImmune by drug maker AstraZeneca. AstraZeneca claims that the proposed acquisition is important for the company since it will boost its weak pipeline and will give it access to the area of...

  • Autonomy lost.  // Nature;11/1/2007, Vol. 450 Issue 7166, p17 

    The article reports on the merger between Cambridge Antibody Technology Group PLC (CAT) and MedImmune Inc. on October 29, 2007 in Gaithersburg, Maryland . It relates that both companies will be under the management of AstraZeneca PLC which acquired CAT in 2006 and MedImmune Inc. on April 2007...

  • AZ to buy CAT.  // European Pharmaceutical Executive;Jul/Aug2006, p12 

    The article reports that AstraZeneca PLC has acquired Cambridge Antibody Technology (CAT) for 702 million pounds in Great Britain. The acquisition is expected to accelerate AstraZeneca's delivery of new medicines for certain disease areas, considering monoclonal antibodies and novel biological...

  • COMPANY SPOTLIGHT - Medlmmune.  // PharmaWatch: Monthly Review;Dec2005, Vol. 4 Issue 12, p37 

    The article presents information about the pharmaceutical company MedImmune Inc. The company has recently completed an acquisition of Cellective Therapeutics, a biopharmaceutical company focused on the development of therapeutic monoclonal antibodies targeting B-lymphocyte receptors. MedImmune's...

  • FDA Issues Complete Response for MedImmune Lung Drug. Young, Donna // BioWorld Today;12/2/2008, Vol. 19 Issue 233, p1 

    The article reports on an announcement by MedImmune Inc. and its parent company AstraZeneca plc that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for motavizumab, a monoclonal antibody from under investigation as a therapy to prevent serious respiratory...

  • AstraZeneca Folds Cambridge Antibody Into MedImmune. Boggs, Jennifer // BioWorld International;10/31/2007, Vol. 12 Issue 44, p3 

    The article reports on the planned merger of MedImmune Inc. and Cambridge Antibody Technology (CAT), which is part of the efforts of AstraZeneca plc to replenish its dwindling drug pipeline. Under the plan, MedImmune will absorb CAT's operations, along with other biologics activities within...

  • Come On, Life Sciences, Let's Feel The Hostility. Thiel, Karl // BioWorld Today;11/26/2007, Vol. 18 Issue 228, p1 

    The article addresses the issue of hostility in the life sciences industry focusing on the acquisition of MedImmune by AztraZeneca. AstraZeneca paid $15.6 billion for MedImmune in June 2007. The acquisition represents about a 21% premium to the stock price just before the deal was announced, and...

  • AstraZeneca Folds Cambridge Antibody Into MedImmune. Boggs, Jennifer // BioWorld Today;10/30/2007, Vol. 18 Issue 211, p1 

    The article reports that AstraZeneca plc will merge its acquisitions MedImmune Inc. and Cambridge Antibody Technology into an independent biologics subsidiary. Accordingly, MedImmune will take in the operations of Cambridge Antibody Technology along with other biological activities within...

  • MedImmune Offer High: AstraZeneca To Pay $15.2B.  // Bioworld Week;4/30/2007, Vol. 15 Issue 18, p1 

    The article reports on the approval of MedImmune Inc. to be acquired by AstraZeneca PLC for 415.2 million in the U.S. The agreement calls for AstraZeneca to pay $58 in cash for each MedImmune share, a significant premium to the already-increased price when MedImmune was exploring the sale of the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics